A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood (Orcagraft) With Single Agent Graft-Versus-Host Disease Prophylaxis, In Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cel | Froedtert & the Medical College of Wisconsin

Protocol No

ORCA-GRAFT-OGFT001-001

Principal Investigator

Sameem Abedin

Phase

Summary

To find out more about a new type of blood stem cell transplant, OrcaGraft, in people with blood cancers and myelodysplastic syndromes.

Description

Study of Engineered Donor Grafts (OrcaGraft) in Recipients Undergoing Allogenic BMT for Heme Malignancies

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL

ClinicalTrials.gov

go to website

A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood (Orcagraft) With Single Agent Graft-Versus-Host Disease Prophylaxis, In Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies